Skip to content

Trial Summary

A Phase 1, First-in-Human, Open-label, Single-Arm study of SUPLEXA™ therapy in Patients with Metastatic Solid Tumors and Haematologic Malignancies

Acronym:

SUPLEXA

ACTRN/NCT /ethics:

NCT05237206

Scientific title:

Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies

Sponsor / Cooperative group:

Alloplex Biotherapeutics Inc

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2022-03-08
Anticipated End Date2024-03-08

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Emailadmin@cancerresearchsa.com.au
Phone08 8359 2565
Principal InvestigatorA/Prof Rohit Joshi
Recruitment StatusRecruiting